Glucagon-like peptide-1 receptor agonists (GLP-1 RA), such as Exenatide, Liraglutide, Dulaglutide, and Semaglutide, are considered an evolution in the treatment of T2DM. The gene discussed is GCG; the disease is type 2 diabetes mellitus.